These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17923610)

  • 1. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?
    Trojano M
    Neurology; 2007 Oct; 69(15):1478-9. PubMed ID: 17923610
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?
    Wilkins DE
    Neurology; 2008 Aug; 71(6):463; author reply 463-4. PubMed ID: 18678834
    [No Abstract]   [Full Text] [Related]  

  • 3. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis.
    Trojano M; Russo P; Fuiani A; Paolicelli D; Di Monte E; Granieri E; Rosati G; Savettieri G; Comi G; Livrea P;
    Mult Scler; 2006 Oct; 12(5):578-85. PubMed ID: 17086903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. observational studies: propensity score analysis of non-randomized data.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Di Renzo V
    Int MS J; 2009 Sep; 16(3):90-7. PubMed ID: 19878631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis.
    Renoux C; Suissa S
    Ann Neurol; 2008 Jul; 64(1):109-10; author reply 110. PubMed ID: 18668635
    [No Abstract]   [Full Text] [Related]  

  • 7. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
    Izquierdo G; García-Agua Soler N; Rus M; García-Ruiz AJ
    Brain Behav; 2015 Jun; 5(6):e00337. PubMed ID: 26085963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.
    Alping P; Piehl F; Langer-Gould A; Frisell T;
    Epidemiology; 2019 Mar; 30(2):230-233. PubMed ID: 30721167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not every patient with multiple sclerosis should be treated at time of diagnosis.
    Pittock SJ; Weinshenker BG; Noseworthy JH; Lucchinetti CF; Keegan M; Wingerchuk DM; Carter J; Shuster E; Rodriguez M
    Arch Neurol; 2006 Apr; 63(4):611-4. PubMed ID: 16606780
    [No Abstract]   [Full Text] [Related]  

  • 12. Postmarketing evidence of disease-modifying drugs in multiple sclerosis.
    Trojano M; Paolicelli D; Fuiani A; Pellegrini F; Iaffaldano P; Direnzo V; D'Onghia M
    Neurol Sci; 2008 Sep; 29 Suppl 2():S225-6. PubMed ID: 18690499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
    Frohman EM; Havrdova E; Lublin F; Barkhof F; Achiron A; Sharief MK; Stuve O; Racke MK; Steinman L; Weiner H; Olek M; Zivadinov R; Corboy J; Raine C; Cutter G; Richert J; Filippi M
    Arch Neurol; 2006 Apr; 63(4):614-9. PubMed ID: 16606781
    [No Abstract]   [Full Text] [Related]  

  • 14. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple sclerosis: combination therapy in MS--still a valid strategy.
    Kieseier BC; Stüve O
    Nat Rev Neurol; 2011 Oct; 7(12):659-60. PubMed ID: 22009284
    [No Abstract]   [Full Text] [Related]  

  • 16. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness.
    Wolfe F; Michaud K
    Rheumatology (Oxford); 2005 Dec; 44 Suppl 4():iv18-iv22. PubMed ID: 16306476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How (in-)complete are study reports?].
    Rakowitz B
    Dtsch Med Wochenschr; 2011 Apr; 136(15):752. PubMed ID: 21488003
    [No Abstract]   [Full Text] [Related]  

  • 18. Autoimmune diseases. The B cell slayer.
    Matthews R
    Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre.
    Goodin DS
    J Neurol; 2006 Jul; 253(7):947-8; author reply 949. PubMed ID: 16845567
    [No Abstract]   [Full Text] [Related]  

  • 20. Vascular registries join to create a common international dataset on AAA surgery.
    Björck M; Gibbons CP; Jensen LP; Laustsen J; Lees T; Moreno-Carriles R; Troëng T; Wigger P
    Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):257-9. PubMed ID: 17616407
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.